Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.

< BACK TO ARCHIVE


2020 Mar 09


Med Lett Drugs Ther


http://www.ncbi.nlm.nih.gov/pubmed/32555120?dopt=Abstract


62


1593

Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.

Authors

Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.
Med Lett Drugs Ther. 2020 Mar 09; 62(1593):35-39.
PMID: 32555120.